NCT07461454 2026-03-10
YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 3 Not yet recruiting
Clinical Trials
7 trialsNCT07406542 2026-02-12
A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 3 Not yet recruiting
NCT06857747 2025-03-04
Disitamab Vedotin in Combination with Metronomic Chemotherapy in Advanced HER2-expressing Breast Cancer.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase NA Not yet recruiting
NCT06653972 2024-10-23
EASOVCWDITHABC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT06229067 2024-01-29
Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT05901935 2023-06-13
DP303c in Patients With HER2-positive Advanced Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 3 Not yet recruiting
NCT04922008 2021-06-10
Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS-C/D)
Fudan University
Phase 2 Not yet recruiting